EGFR and cancer: Molecular targeted therapy has changed the cancer treatment paradigm, with many targeted agents, including ALK tyrosine kinase inhibitor (ALK-TKI) and EGFR tyrosine kinase inhibitor (EGFR-TKI) now standard therapies for patients harboring a corresponding molecular target.